WITHDRAWN: Cernilton for benign prostatic hyperplasia.

Keyphrases

• Placebo 100%
• Benign Prostatic Hyperplasia 100%
• Nocturia 37%
• Risk Ratio 37%
• Urologic Symptoms 37%
• Lower Urinary Tract Symptoms 25%
• Comparative Trial 25%
• Symptom Scale 25%
• Urodynamics 25%
• Urinary Symptoms 25%
• Prostate Size 25%
• Residual Volume 25%
• Placebo-controlled 12%
• Randomized Placebo-controlled Trial 12%
• Clinical Efficacy 12%
• Prostate 12%
• Randomized Controlled Trial 12%
• Patient Outcomes 12%
• Active Control 12%
• Clinical Safety 12%
• Ryegrass 12%
• Plant Use 12%
• Adverse Events 12%
• Patient-centered Intervention 12%
• Pharmacologic 12%
• Controlled Experiment 12%
• Secale Cereale 12%
• Enlargement 12%
• Symptom Score 12%
• MEDLINE 12%
• Embase 12%
• Nonmalignant 12%
• Cochrane Library 12%
• Urinary Flow 12%
• Urinary Flow Rate 12%
• Grass Pollen 12%
• Double-blind Method 12%
• Allocation Concealment 12%
• Withdrawal Rate 12%
• Treatment Allocation 12%
• Specialized Databases 12%
• Flow Measuring 12%
• Urine Flow 12%
• Phytopharmaceuticals 12%
• Irritative 12%
• Phytotherapy 12%
• Active-controlled Trial 12%
• Clinical Outcomes 12%
• Volume Size 12%

Medicine and Dentistry

• Prostate Hypertrophy 100%
• Cernitin 100%
• Placebo 83%
• Paraprost 25%
• Nocturia 25%
• Urodynamics 16%
• Lower Urinary Tract Symptom 16%
• Urinary System 16%
• Residual Volume 16%
• Pygeum Africanum Extract 16%
• Side Effect 16%
• Systematic Review 8%
• Randomized Controlled Trial 8%
• Adverse Event 8%
• Controlled Clinical Trial 8%
• Urine Flow Rate 8%
• Micturition 8%
• Grass Pollen 8%
• Independent Reviewer 8%
• Phytotherapy 8%
• Agent Study 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Prostate Hypertrophy 100%
• Cernitin 100%
• Placebo 83%
• Paraprost 25%
• Nocturia 25%
• Rye 16%
• Pygeum Africanum Extract 16%
• Lower Urinary Tract Symptom 16%
• Side Effect 16%
• Controlled Clinical Trial 8%
• Randomized Controlled Trial 8%
• Adverse Event 8%
• Phytotherapy 8%